Health Care [ 12/12 ] | Health Care Equipment & Supplies [ 46/74 ]
NYSE | Common Stock
Paragon 28, Inc. develops, distributes, and sells foot and ankle surgical systems in the United States and internationally.
It offers plating systems, including gorilla plating systems, such as lisfranc, lapidus, lateral column, calcaneus slide, and naviculocuneiform (NC) fusion plating systems; baby gorilla plate-specific screws, navicular fracture plates, and 5th metatarsal hook plates; and silverback plating systems.
The company also provides precision guide technology for various procedures consisting of fusion, a procedure to address bunion deformities that fuses two bones on the big toe; first tarsometatarsal arthrodesis; and metatarsal osteotomy for bunion correction, medial column beaming for charcot foot reconstruction, ankle fusion plating, and NC joint arthrodesis.
In addition, it offers monster, mini monster, and joust beaming screw systems for use in bone reconstruction, osteotomy, arthrodesis, joint fusion, ligament fixation, fracture repair, and fracture fixation; APEX 3D total ankle replacement systems; and total talus spacers to replace the talus and bone in the ankle that connects the leg and foot.
Further, the company provides forefoot or hallux valgus correction systems, including phantom intramedullary nail systems for the treatment of severe hallux valgus; and various orthobiologics comprising bone wedges, grafts, demineralized bone matrices, bone void fillers, synthetic materials, amniotic products, and a biocompatible collagen matrix, as well as PRESERVE bone graft systems for homologous application.
Additionally, it offers soft tissue fixation systems, titanium sprayed polyetheretherketone implants, nitinol staple systems, stabilization systems, and curved instruments.
The company serves hospitals and ambulatory surgery centers through a network of sales representatives and stocking distributors.
Paragon 28, Inc. was founded in 2010 and is headquartered in Englewood, Colorado.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 8, 24 | -0.17 Decreased by -30.77% | -0.17 |
| May 8, 24 | -0.18 Decreased by -63.64% | -0.12 Decreased by -50.00% |
| Feb 29, 24 | -0.23 Decreased by -53.33% | -0.09 Decreased by -155.56% |
| Nov 7, 23 | -0.10 Increased by +23.08% | -0.10 |
| Aug 2, 23 | -0.13 Increased by 0.00% | -0.10 Decreased by -30.00% |
| May 4, 23 | -0.11 Increased by +8.33% | -0.10 Decreased by -10.00% |
| Mar 2, 23 | -0.15 Decreased by -87.50% | -0.10 Decreased by -50.00% |
| Nov 10, 22 | -0.13 Decreased by -8.33% | -0.12 Decreased by -8.33% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 62.34 M Increased by +18.10% | -12.34 M Decreased by -48.08% | Decreased by -19.79% Decreased by -25.39% |
| Jun 30, 24 | 61.02 M Increased by +19.62% | -13.78 M Decreased by -26.46% | Decreased by -22.59% Decreased by -5.72% |
| Mar 31, 24 | 61.08 M Increased by +17.38% | -15.23 M Decreased by -68.29% | Decreased by -24.94% Decreased by -43.37% |
| Dec 31, 23 | 60.56 M Increased by +17.58% | -19.56 M Increased by +49.54% | Decreased by -32.30% Increased by +57.08% |
| Sep 30, 23 | 52.78 M Increased by +14.73% | -8.33 M Increased by +14.32% | Decreased by -15.79% Increased by +25.32% |
| Jun 30, 23 | 51.01 M Increased by +20.03% | -10.90 M Decreased by -13.49% | Decreased by -21.36% Increased by +5.45% |
| Mar 31, 23 | 52.04 M Increased by +25.78% | -9.05 M Increased by +1.99% | Decreased by -17.40% Increased by +22.08% |
| Dec 31, 22 | 51.51 M Increased by +20.42% | -38.76 M Decreased by -527.84% | Decreased by -75.26% Decreased by -421.38% |